A S X A N N O U N C E M E N T 1 6 N o v e m b e r 2 0 2 6 Encouraging FDA Pre-IND feedback for VB0004 in IPF HIGHLIGHTS • The U.S. Food and Drug Administration's (FDA) written responses have been received from the Division of Pulmonology, Allergy and Critical Care (DPACC). • The feedback...
FDA Pre-IND feedback for VB0004
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The FDA's written responses provide supportive guidance on the company's chemistry, manufacturing, and clinical plans for the drug. Vectus plans to incorporate this feedback into its Investigational New Drug package as it prepares for a Phase Ib / IIa study.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Vectus Biosystems Limited on 6ix
Earlier from Vectus Biosystems
- Appointment of Prof Tamera Corte as Chief Clinical Advisor
- Notification regarding unquoted securities - VBS
- Quarterly Activities & Appendix 4C Cash Flow Reports
- Results of 2026 AGM
- 2026 AGM Presentations
Follow Vectus Biosystems into a list and get an email when it puts out news.
Follow Vectus Biosystems